LIMK2 inhibitors, compositions comprising them, and methods of their use

1. A method of lowering intraocular pressure in a patient, which comprises administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof, wherein:

R 3A is cyano, C(O)R 3C , CO 2 R 3C , CON(R 3C ) 2 , or optionally substituted alkyl, alkylaryl, alkylheterocycle, aryl, heteroalkyl, heteroalkylaryl, heteroalkylheterocycle, or heterocycle;

each R 3C is independently optionally substituted alkyl, aryl or heterocycle; and

each R 4A is independently hydrogen or optionally substituted alkyl or heteroalkyl.

2. The method of claim 1 , wherein R 3A is heteroalkyl.

3. The method of claim 2 , wherein R 3A is aminomethyl, (dimethylamino)methyl, or (dimethylamino)ethyl.

4. The method of claim 1 , wherein at least one R 4A is methyl.

5. The method of claim 1 , wherein the compound is 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate.

6. The method of claim 1 , wherein the compound is administered in a pharmaceutical formulation comprising a liquid vehicle suitable for ophthalmic administration.

7. A method of lowering intraocular pressure in a patient, which comprises administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical formulation comprising 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate and a liquid vehicle suitable for ophthalmic administration.